Contact this trialFirst, we need to learn more about you.
Anti-tumor antibiotic
NEROFE + Doxorubicin for Solid Tumors
Recruiting1 awardPhase 1
Washington, District of Columbia
This trial is testing the safety and effectiveness of combining NEROFE, a new cancer drug, with doxorubicin, a chemotherapy medication. It focuses on patients with advanced or hard-to-treat solid tumors. NEROFE may help target cancer cells more precisely, while doxorubicin prevents them from multiplying. The goal is to find the best way to use this combination treatment.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service